tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GLUE Stock Latest News

Monte Rosa Therapeutics presents preclinical data on MRT-8102
The FlyMonte Rosa Therapeutics presents preclinical data on MRT-8102
3d ago
GLUE
Monte Rosa Therapeutics Reports Strong Revenue Growth
PremiumCompany Announcements
Monte Rosa Therapeutics Reports Strong Revenue Growth
6d ago
GLUE
Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating
PremiumRatings
Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating
6d ago
GLUE
Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
PremiumRatings
Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
6d ago
GLUE
Monte Rosa Announces Q3 Results and Novartis Collaboration
PremiumCompany Announcements
Monte Rosa Announces Q3 Results and Novartis Collaboration
7d ago
8K
GLUE
Monte Rosa Therapeutics reports Q3 revenue $12.8M, consensus $7.37M
PremiumThe FlyMonte Rosa Therapeutics reports Q3 revenue $12.8M, consensus $7.37M
7d ago
GLUE
Monte Rosa Therapeutics sees cash runway through 2028
Premium
The Fly
Monte Rosa Therapeutics sees cash runway through 2028
7d ago
GLUE
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study
Premium
Company Announcements
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study
16d ago
GLUE
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study
PremiumCompany Announcements
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study
16d ago
GLUE
Monte Rosa Therapeutics presents preclinical data at ACR on MRT-6160
PremiumThe Fly
Monte Rosa Therapeutics presents preclinical data at ACR on MRT-6160
20d ago
GLUE
Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups
PremiumMarket News
Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups
1M ago
NVS
PFE
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
2M ago
HD
MU
Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz
PremiumThe FlyTesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz
2M ago
MU
UA
Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
Premium
Market News
Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
2M ago
NVS
ARWR
Monte Rosa Therapeutics Partners with Novartis for Immunology
Premium
Company Announcements
Monte Rosa Therapeutics Partners with Novartis for Immunology
2M ago
8K
GLUE
Monte Rosa Therapeutics announces collaboration with Novartis
PremiumThe Fly
Monte Rosa Therapeutics announces collaboration with Novartis
2M ago
NVS
GLUE
Monte Rosa Therapeutics Reports Q2 2025 Earnings
PremiumCompany Announcements
Monte Rosa Therapeutics Reports Q2 2025 Earnings
3M ago
GLUE
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential
PremiumRatings
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential
3M ago
GLUE
Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M
PremiumThe Fly
Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M
3M ago
GLUE
Monte Rosa Therapeutics management to meet with Piper Sandler
PremiumThe FlyMonte Rosa Therapeutics management to meet with Piper Sandler
4M ago
GLUE
Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102
Premium
The Fly
Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102
4M ago
GLUE
Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102
Premium
The Fly
Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102
5M ago
GLUE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >